Correlation Between Crispr Therapeutics and Natera

Can any of the company-specific risk be diversified away by investing in both Crispr Therapeutics and Natera at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Crispr Therapeutics and Natera into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Crispr Therapeutics AG and Natera Inc, you can compare the effects of market volatilities on Crispr Therapeutics and Natera and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Crispr Therapeutics with a short position of Natera. Check out your portfolio center. Please also check ongoing floating volatility patterns of Crispr Therapeutics and Natera.

Diversification Opportunities for Crispr Therapeutics and Natera

-0.67

Correlation Coefficient

Crispr Therapeutics  Natera

Excellent diversification

The 3 months correlation between Crispr and Natera is -0.67. Overlapping area represents the amount of risk that can be diversified away by holding Crispr Therapeutics AG and Natera Inc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Natera Inc and Crispr Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Crispr Therapeutics AG are associated (or correlated) with Natera. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Natera Inc has no effect on the direction of Crispr Therapeutics i.e., Crispr Therapeutics and Natera go up and down completely randomly.

Pair Corralation between Crispr Therapeutics and Natera

Given the investment horizon of 90 days Crispr Therapeutics is expected to generate 3.87 times less return on investment than Natera. In addition to that, Crispr Therapeutics is 1.93 times more volatile than Natera Inc. It trades about 0.03 of its total potential returns per unit of risk. Natera Inc is currently generating about 0.24 per unit of volatility. If you would invest  17,381  in Natera Inc on September 11, 2025 and sell it today you would earn a total of  5,932  from holding Natera Inc or generate 34.13% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Crispr Therapeutics AG  vs.  Natera Inc

Crispr Therapeutics

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Crispr Therapeutics AG are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Crispr Therapeutics may actually be approaching a critical reversion point that can send shares even higher in January 2026.

Natera Inc

Risk-Adjusted Performance

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Natera Inc are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady basic indicators, Natera sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Crispr Therapeutics and Natera

The main advantage of trading using opposite Crispr Therapeutics and Natera positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Crispr Therapeutics position performs unexpectedly, Natera can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Natera will offset losses from the drop in Natera's long position.

The idea behind Crispr Therapeutics AG and Natera Inc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.